ZI
Zim Laboratories Ltd (ZIMLAB)
₹138.63
Mkt cap
₹727 Cr
P/E ratio
197.00
P/B
2.50
Div yield
0.00%
ROE
1.59%
ROCE
4.76%
EPS (TTM)
₹0.70
Book value
₹55
52W range
59–144
Sector
Healthcare
Price history
Previous close
Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India [1]
NSE ZIMLABBSE 541400
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−4.06% from high₹139
₹59+133.74% from low₹144
Current
₹138.63
Prev close
₹139.00
Day
−0.27%
Price performance
1D
−0.27%
1W
+0.79%
1M
+8.29%
3M
+14.86%
6M
+105.47%
1Y
+89.31%
YTD
+96.83%
Financials
Revenue, profit & margin
P/E ratio
197.0×
ZIMLAB is 470% above the sector median of 34.6×
ZIMLAB197.0×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67.44 | 85.83 | 96.29 | 117.86 | 81.82 | 92.14 | 96.33 | 108.73 | 71.76 | 88.71 | 108.66 | 105.27 | 94.18 | |
| Expenses | 62.62 | 76.50 | 84.75 | 102.21 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 | |
| Operating Profit | 4.82 | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.60 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 | |
| OPM % | 7.15% | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.60% | |
| Other Income | 1.12 | 1.42 | 1.11 | 1.53 | 1.00 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.70 | 6.16 | 0.99 | |
| Interest | 1.73 | 1.22 | 1.70 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.30 | 3.16 | 3.43 | 3.31 | 3.64 | |
| Depreciation | 4.03 | 4.09 | 3.94 | 3.91 | 4.94 | 5.00 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.10 | 5.37 | |
| Profit before tax | 0.18 | 5.44 | 7.01 | 10.99 | 1.24 | 2.96 | 5.70 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 | |
| Tax % | -22.22% | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% | |
| Net Profit | 0.23 | 4.15 | 4.78 | 8.09 | 0.90 | 2.38 | 4.00 | 4.88 | -1.87 | -0.42 | 4.40 | 3.74 | -4.02 | |
| EPS in Rs | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 | -0.75 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.75% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | −2.75% |
| +1 day | −3.46% |
| +5 days | −6.60% |
| +15 days | +8.95% |
| +30 days | +16.07% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202630.36%Promoter
Promoters30.36%
FIIs0.03%0.03
DIIs1.34%1.27
Public68.28%1.29
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Zim Laboratories | ₹135.51 | 196.52 | 727 | 0.00% | −4 | −114.97% | 94 | +31.24% | 4.76% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports12
Concall transcripts32
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024PPTAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Updates on Acquisition 18 Sep - ZIM Laboratories SpA incorporated in Chile on 9 September 2026 as a wholly owned subsidiary for LATAM expansion.Announcement under Regulation 30 (LODR)-Updates on Acquisition 15 Sep - ZIM FZE completed approved investment in ZIM Scientific Office LLC, retaining 100% holding.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 12 AugShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 12 Aug - Postal ballot passed on 11 Aug 2026 approving remuneration revisions for MD Dr. Anwar Daud and WTD Mr. Zulfiquar Kamal.Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 12 Aug - Postal ballot special resolutions passed on 11 Aug 2026 to revise remuneration for MD and WTD.